Pseudovitelliform maculopathy secondary to BRAF and MEK inhibitors in a patient with metastasic melanoma

J Biol Regul Homeost Agents. 2019;33(5):1497-1500. doi: 10.23812/19-89-L.

Authors

C Alba-Linero¹, C Rocha De Lossada¹, A S Delgado-Fernández¹, M Jódar-Márquez¹, M Rodríguez Calvo De Mora¹, M A Berciano-Guerrero²

Affiliations

¹ Ophthalmology Department, Hospital Regional Málaga, Plaza del Hospital Civil, Málaga, Spain.
² Oncology Department. Hospital Regional Málaga, Málaga, Spain.

PMID: 31583878
DOI: 10.23812/19-89-L

No abstract available

Keywords: BRAF inhibitors; MEK inhibitors; metastasic melanoma; neuroepithelial detachment; pseudovitelliform.

Publication types

Letter

MeSH terms

Humans
Macular Degeneration / chemically induced*
Melanoma / drug therapy*
Melanoma / pathology
Neoplasm Metastasis
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / metabolism*
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf